GO
Loading...

Gilead Sciences Inc

More

  • Final Glance: Biotechnology companies Wednesday, 22 Oct 2014 | 6:09 PM ET

    Amgen Inc. fell$. 45 or. 3 percent, to $143.64. Biogen Idec fell $17.70 or 5.4 percent, to $309.07. Celgene Corp. fell$. 21 or. 2 percent, to $94.76.

  • Midday Glance: Biotechnology companies Wednesday, 22 Oct 2014 | 1:18 PM ET

    Amgen Inc. fell $1.59 or 1.1 percent, to $142.50. Biogen Idec fell $23.54 or 7.2 percent, to $303.23. Celgene Corp. fell$. 60 or. 6 percent, to $94.37.

  • Early Glance: Biotechnology companies Wednesday, 22 Oct 2014 | 10:36 AM ET

    Amgen Inc. fell $1.16 or. 8 percent, to $142.93. Biogen Idec fell $21.61 or 6.6 percent, to $305.16. Celgene Corp. rose $1.23 or 1.3 percent, to $96.20.

  • Final Glance: Biotechnology companies Tuesday, 21 Oct 2014 | 6:01 PM ET

    Amgen Inc. rose $6.58 or 4.8 percent, to $144.09. Biogen Idec rose $15.36 or 4.9 percent, to $326.77. Celgene Corp. rose $2.97 or 3.2 percent, to $94.97.

  • Midday Glance: Biotechnology companies Tuesday, 21 Oct 2014 | 1:43 PM ET

    Amgen Inc. rose $1.96 or 1.4 percent, to $139.47. Biogen Idec rose $8.12 or 2.6 percent, to $319.53. Celgene Corp. rose $2.57 or 2.8 percent, to $94.57.

  • Early Glance: Biotechnology companies Tuesday, 21 Oct 2014 | 11:56 AM ET

    Amgen Inc. rose $1.55 or 1.1 percent, to $139.06. Biogen Idec rose $6.48 or 2.1 percent, to $317.89. Celgene Corp. rose $3.34 or 3.6 percent, to $95.34.

  • Final Glance: Biotechnology companies Monday, 20 Oct 2014 | 6:05 PM ET

    Amgen Inc. rose $3.82 or 2.9 percent, to $137.51. Biogen Idec rose $4.70 or 1.5 percent, to $311.41. Celgene Corp. rose $3.88 or 4.4 percent, to $92.00.

  • Midday Glance: Biotechnology companies Monday, 20 Oct 2014 | 1:23 PM ET

    Amgen Inc. rose$. 35 or. 3 percent, to $134.04. Biogen Idec rose $3.41 or 1.1 percent, to $310.12. Celgene Corp. rose $3.24 or 3.7 percent, to $91.36.

  • Early Glance: Biotechnology companies Monday, 20 Oct 2014 | 10:40 AM ET

    Amgen Inc. rose$. 93 or. 7 percent, to $134.62. Biogen Idec rose $2.07 or. 7 percent, to $308.78. Celgene Corp. rose $1.72 or 2.0 percent, to $89.84.

  • Final Glance: Biotechnology companies Friday, 17 Oct 2014 | 6:03 PM ET

    Amgen Inc. rose $3.24 or 2.5 percent, to $133.69. Biogen Idec rose $3.97 or 1.3 percent, to $306.71. Celgene Corp. rose $1.74 or 2.0 percent, to $88.12.

  • Midday Glance: Biotechnology companies Friday, 17 Oct 2014 | 1:21 PM ET

    Amgen Inc. rose $3.30 or 2.5 percent, to $133.75. Biogen Idec rose $9.17 or 3.0 percent, to $311.91. Celgene Corp. rose $3.04 or 3.5 percent, to $89.42.

  • Early Glance: Biotechnology companies Friday, 17 Oct 2014 | 10:39 AM ET

    Amgen Inc. rose$. 25 or. 2 percent, to $130.70. Biogen Idec rose $8.00 or 2.6 percent, to $310.74. Celgene Corp. rose $2.45 or 2.8 percent, to $88.83.

  • Final Glance: Biotechnology companies Thursday, 16 Oct 2014 | 6:02 PM ET

    Amgen Inc. fell$. 45 or. 3 percent, to $130.45. Biogen Idec fell $2.95 or 1.0 percent, to $302.74. Celgene Corp. fell$. 17 or. 2 percent, to $86.38.

  • Midday Glance: Biotechnology companies Thursday, 16 Oct 2014 | 1:21 PM ET

    Amgen Inc. fell $1.85 or 1.4 percent, to $129.05. Biogen Idec fell $2.23 or. 7 percent, to $303.46. Celgene Corp. fell$. 18 or. 2 percent, to $86.37.

  • Early Glance: Biotechnology companies Thursday, 16 Oct 2014 | 11:35 AM ET

    Amgen Inc. fell $1.81 or 1.4 percent, to $129.09. Biogen Idec fell $2.69 or. 9 percent, to $303.00. Celgene Corp. fell $1.56 or 1.8 percent, to $84.99.

  • BOSTON, Oct 16- Some of Wall Street's biggest names are licking their wounds as October lives up to its reputation as one of the market's roughest months. Morgan Stanley strategists said this week that their model portfolio through Monday had trailed the S&P by 3.6 percentage points due to bad bets on technology stocks, including GT Advanced Technologies, the...

  • Final Glance: Biotechnology companies Wednesday, 15 Oct 2014 | 6:07 PM ET

    Amgen Inc. fell $1.30 or 1.0 percent, to $130.90. Biogen Idec rose $4.11 or 1.4 percent, to $305.69. Celgene Corp. rose$. 07 or. 1 percent, to $86.55.

  • The first, Esbriet, was developed by InterMune Inc, which Switzerland- based Roche Holding AG agreed to buy for $8.3 billion in August, banking largely on the treatment's potential. The agency's decision marks a crucial milestone in the management of the disease, which affects about 100,000 people in the United States. Roche's drug, known generically as...

  • Midday Glance: Biotechnology companies Wednesday, 15 Oct 2014 | 1:17 PM ET

    Amgen Inc. fell $2.15 or 1.6 percent, to $130.05. Biogen Idec rose $5.29 or 1.8 percent, to $306.87. Celgene Corp. fell $1.36 or 1.6 percent, to $85.12.

  • Early Glance: Biotechnology companies Wednesday, 15 Oct 2014 | 10:46 AM ET

    Amgen Inc. fell $1.56 or 1.2 percent, to $130.64. Biogen Idec rose $1.69 or. 6 percent, to $303.27. Celgene Corp. fell$. 90 or 1.0 percent, to $85.58.